Curi Bio Recognized as a 2024 Deloitte Technology Fast 500 Winner

Seattle, WA – November 22, 2024 [originally posted on Business Wire] – Curi Bio, the industry leader in developing human stem cell-based platforms for drug discovery, is proud to announce its selection as one of Deloitte's Technology Fast 500™ companies in 2024, an annual ranking of the 500 fastest-growing technology companies in North America. Curi Bio achieved an overall rank of #123 and secured #18 out of the 70 life sciences companies recognized, highlighting Curi Bio’s leadership in advancing predictive, human-relevant technologies for drug discovery. Curi Bio was selected due to its strong and steady revenue growth which is a consequence of the pharmaceutical industry’s rapid adoption of the company’s leading biological models.

"We are honored to be recognized among North America’s most innovative and fastest-growing life sciences companies," said Dr. Nicholas A. Geisse, CEO at Curi Bio. "This recognition reflects the dedication of our team and the groundbreaking impact of our human-relevant platforms. By providing drug developers tools that more accurately replicate human physiology, our work has accelerated timelines and continues improving the safety and efficacy of new therapies for patients suffering from some of the world’s most devastating diseases."

Curi Bio’s innovative human stem cell platforms deliver functional data that enable biopharmaceutical researchers to make more informed, data-driven decisions. By delivering predictive, human-relevant insights, Curi Bio’s technology accelerates the development of safer and more effective drugs, addressing critical challenges in a rapidly evolving industry. The company’s portfolio of functional human disease models spans cardiac, skeletal muscle, and neuromuscular indications, offering researchers powerful tools to tackle some of the most complex diseases beyond the constraints of costly and risky clinical trials. This approach of empowering researchers with turnkey platforms has been a cornerstone of Curi Bio’s growth, earning recognition with this award and demonstrating its pivotal role in advancing medical science.

About the 2024 Deloitte Technology Fast 500

Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Curi Bio

Curi Bio unlocks novel workflows and delivers functional human data to inform biopharmaceutical R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio melds functional and analytical assessments for drug safety, efficacy, and potency. By offering leading global pharmaceutical end users an integrated preclinical platform along with highly predictive human stem cell tissue models to generate clinically-relevant data, Curi Bio is bridging the gap between preclinical R&D and clinical outcomes, accelerating the discovery and development of safer, more effective medicines.

For more information, please visit www.curibio.com.